Heart Transplantation in the Elderly Patients: Midterm Results

Sang Yoon Yeom, M.D.1, Ho Young Hwang, M.D., Ph.D.1, Se-Jin Oh, M.D., Hyun-Jai Cho, M.D., Ph.D.2, Hae-Young Lee, M.D., Ph.D.2, Ki-Bong Kim, M.D., Ph.D.1

Background: Heart transplantation in elderly patients has raised concerns because of co-morbidities and limited life expectancy in the era of donor shortage. We examined the outcomes after heart transplantation in elderly patients.

Materials and Methods: From March 1994 to December 2011, 81 patients (male:female=64:17, 49.1±14.0 years) underwent heart transplantation. The outcomes after heart transplantation in the younger patients (<60 years; group Y, n=60) were compared with those in the elderly patients (≥60 years; group O, n=21). The follow-up duration was 51.8±62.7 months. Results: Early mortality (≤30 days) occurred in 5.0% (3/60) and 4.8% (1/21) of groups Y and O, respectively (p>0.999). There were no differences in overall survival between the two groups (p=0.201). Freedom from rejection was higher in group O than in group Y (p=0.026). Multivariable analysis revealed that age ≥60 years was not a significant risk factor for long-term survival; postoperative renal failure was the only significant risk factor for long-term survival (p=0.011). Conclusion: Early and mid-term results of heart transplantation in elderly patients were similar to those in younger patients.

Key words: 1. Heart transplantation 2. Outcome assessment 3. Elderly

INTRODUCTION

Heart transplantation has evolved into the gold standard treatment for patients with end-stage congestive heart failure [1]. As outcomes of heart transplantation have improved, the number of patients waiting for heart transplantation has markedly increased, and the upper limit of the recipient’s age has been raised in some centers [2-4]. However, it has been suggested that advanced age is considered a relative contraindication for heart transplantation due to the high incidence of co-morbidities such as malignancies, hypertension, diabetes mellitus, and reduced life expectancy after heart transplantation [5,6]. In addition, heart transplantation in elderly patients is still under debate because the shortage of donor hearts has been aggravated. The aim of this study was to evaluate early- and mid-term results of heart transplantation in patients ≥60 years old when compared with those of heart transplantation in patients <60 years old.

MATERIALS AND METHODS

1) Patient characteristics

Between March 1994 and December 2011, 81 patients un-
Table 1. Preoperative characteristics of the study patients

| Variable          | Total (n=81) | Group Y (n=60) | Group O (n=21) | p-value      |
|-------------------|--------------|----------------|----------------|-------------|
| Age (yr)          | 49.1±14.0    | 43.2±11.2      | 65.8±4.1       | <0.001      |
| Female            | 17 (21.0)    | 11 (18.3)      | 6 (28.6)       | 0.358       |
| Diagnosis         |              |                |                | 0.298       |
| DCMP              | 42 (51.9)    | 34 (56.7)      | 8 (38.1)       |            |
| ICMP              | 22 (27.2)    | 14 (23.3)      | 7 (38.1)       |            |
| Others            | 17 (21.0)    | 12 (20.0)      | 5 (23.8)       |            |
| Co-morbidities    |              |                |                |            |
| Diabetes          | 19 (23.5)    | 13 (21.7)      | 6 (28.6)       | 0.557       |
| Hypertension      | 19 (23.5)    | 11 (18.3)      | 8 (38.1)       | 0.079       |
| Dyslipidemia      | 7 (8.6)      | 5 (8.3)        | 2 (9.5)        | >0.999      |
| Renal failure     | 8 (9.9)      | 5 (8.3)        | 3 (14.3)       | 0.421       |
| Stroke            | 6 (7.4)      | 4 (7.3)        | 2 (9.5)        | 0.647       |
| Echocardiographic data |        |                |                |            |
| LVEF (%)          | 22.8±10.4    | 21.8±10.1      | 25.7±10.9      | 0.137       |
| PASP (mmHg)       | 49.7±15.5    | 48.8±15.4      | 52.5±16.1      | 0.395       |

Values are presented as mean±standard deviation or number (%). Group Y, patients <60 years old at transplantation; group O, patients ≥60 years at transplantation.

DCMP, dilated cardiomyopathy; ICMP, ischemic cardiomyopathy; LVEF, left ventricle ejection fraction; PASP, pulmonary artery systolic pressure.

Table 2. Operative data of the study patients

| Variable             | Total (n=81) | Group Y (n=60) | Group O (n=21) | p-value |
|----------------------|--------------|----------------|----------------|---------|
| Redo-operation       | 17 (21.0)    | 13 (21.7)      | 4 (19.0)       | >0.999  |
| Donor age (yr)       | 32.2±10.9    | 31.4±11.1      | 34.2±10.4      | 0.312   |
| Ischemic time (min)  | 155±49       | 147±45         | 177±53         | 0.015   |
| Cardiopulmonary bypass time (min) | 241±77       | 226±65         | 282±92         | 0.004   |

Values are presented as number (%) or mean±standard deviation. Group Y, patients <60 years old at transplantation; group O, patients ≥60 years at transplantation.

Two techniques for heart transplantation were used. In most patients (96.3%), the bicausal Wythenshawe technique (bicausal and single left atrial anastomoses) [7] was used. The conventional Lower and Shumway technique [8] was used in 3 patients (3.7%) who underwent transplantation in the early period. Seventeen patients (21%) had a history of previous cardiac surgery. The mean donor age was 32.2±10.9 years old. The mean cardiopulmonary bypass (CPB) and donor heart ischemic times were 241±77 and 155±49 minutes, respectively. The mean CPB time in group O was significantly longer than that in group Y (p=0.004) (Table 2).

3) Evaluation of mid-term clinical outcomes

The patients underwent regular postoperative follow-up through the outpatient clinic at 3-month or 4-month intervals. The patients were also contacted by telephone for con-
Heart Transplantation in Elderly

Table 3. Early clinical results

| Variable                     | Total (n=81) | Group Y (n=60) | Group O (n=21) | p-value |
|------------------------------|--------------|----------------|----------------|---------|
| Early mortality (<30 day)    | 4 (4.9)      | 3 (5.0)        | 1 (4.8)        | >0.999  |
| Postoperative morbidity      |              |                |                |         |
| Renal failure needed dialysis| 10 (12.3)    | 5 (8.3)        | 5 (23.8)       | 0.116   |
| Bleeding reoperation         | 8 (9.9)      | 4 (6.7)        | 4 (19.0)       | 0.195   |
| Pneumonia                    | 10 (12.3)    | 7 (11.7)       | 3 (14.3)       | 0.714   |
| Wound problem                | 8 (9.9)      | 4 (6.7)        | 4 (19.0)       | 0.195   |
| Atrial fibrillation          | 3 (3.7)      | 2 (3.3)        | 1 (5.0)        | >0.999  |
| Stroke                       | 2 (2.5)      | 0 (0)          | 2 (9.5)        | 0.065   |
| Intensive care unit stay (day)| 11.4±11.2   | 11.5±12.0      | 11.0±9.1       | 0.852   |
| Hospital stay (day)          | 41.2±30.8    | 36.7±22.5      | 54.1±45.3      | 0.103   |

Values are presented as number (%) or mean±standard deviation.
Group Y, patients <60 years old at transplantation; group O, patients ≥60 years at transplantation.

4) Immune suppression protocol

The standard maintenance immune suppression protocol for heart transplantation (so-called “triple therapy”) was used: (1) a calcineurin inhibitor such as cyclosporine or tacrolimus, (2) an antiproliferative agent such as azathioprine (AZA, Imuran) or mycophenolate mofetil (MMF), and (3) corticosteroids such as prednisone or prednisolone [9]. Cyclosporine, AZA, and prednisolone were used in the early period until June 1999. At that point, the antiproliferative agent was changed from AZA to MMF. In July 2009, the calcineurin inhibitor was changed from cyclosporine to tacrolimus with an addition of interleukin-2. Intravenous methylprednisolone (500 mg) was administered intraoperatively and followed by 3 doses (150 mg every 8 hours) postoperatively. Prednisone was then given at a daily dose of 1 mg/kg (per oral steroid) and tapered over six months to 0.1 mg/kg per day.

The patients underwent endomyocardial biopsy weekly for 4 weeks after transplantation, every 4 weeks until the third month, and then every 3 months until the second year. Rejection severity was graded from 0 to 4 based on the International Society for Heart and Lung Transplantation (ISHLT) grading system [10]. Grade 1B and 2 were managed by increasing the dose of oral steroids. Intravenous methylprednisolone (1 g/day for 3 days) was given for ≥grade 3A.

5) Statistical analysis

Statistical analysis was performed using the SPSS ver. 18.0 (SPSS Inc., Chicago, IL, USA). Data were expressed as mean±standard deviation, median and ranges, or proportions. A p-value of less than 0.05 was considered statistically significant. Comparisons between the two groups were performed using the chi-squared or Fisher’s exact test for categorical variables and the Student’s t-test for continuous variables. Survival rates were estimated using the Kaplan-Meier method and comparisons between the 2 groups were performed using the log-rank test. The Cox proportional hazards model was adopted for analysis of risk factors for time related events. The institutional review board of the Seoul National University Hospital approved this study (SNUH IRB No. H-1209-056-425).

RESULTS

1) Early results

There were 4 early mortalities (<30 days): 3 (5.0%) in group Y and 1 (4.8%) in group O (p>0.999). Postoperative morbidities included renal failure requiring dialysis (n=10, 12.3%), bleeding reoperation (n=8, 9.9%), pneumonia (n=10, 12.3%), wound problems (n=8, 9.9%), and atrial fibrillation (n=3, 3.7%). Early mortalities or postoperative complications in the two groups did not differ (Table 3). The intensive care
Fig. 1. Kaplan-Meier curve of overall survival. Group Y, patients <60 years old at transplantation; group O, patients ≥60 years at transplantation.

Fig. 2. Kaplan-Meier curve of freedom from infection. Group Y, patients <60 years old at transplantation; group O, patients ≥60 years at transplantation.

Fig. 3. Kaplan-Meier curve of freedom from rejection. Group Y, patients <60 years old at transplantation; group O, patients ≥60 years at transplantation.

Table 4. Analysis of risk factors for overall survival using the Cox proportional hazard model

| Variable                  | Univariate |         |         | Multivariable |
|---------------------------|------------|---------|---------|---------------|
|                           | p-value    | Hazard ratio | 95% confidence interval | p-value |
| Age (≥60 yr)              | 0.201      | 1.545   | 0.551-4.336 | 0.408 |
| Sex                       | 0.210      | 1.434   | 0.585-3.513 | 0.430 |
| Body surface area (m²)    | 0.630      | -       | -       | -              |
| Diagnosis                 | 0.510      | -       | -       | -              |
| Diabetes                  | 0.529      | -       | -       | -              |
| Hypertension              | 0.843      | -       | -       | -              |
| Redo-operation            | 0.761      | -       | -       | -              |
| PASP (mmHg)               | 0.759      | -       | -       | -              |
| Ischemic time (min)       | 0.420      | -       | -       | -              |
| Bleeding reoperation      | 0.530      | -       | -       | -              |
| ECMO support              | 0.829      | -       | -       | -              |
| Postoperative RF          | 0.003      | 2.991   | 1.279-6.992 | 0.011 |

PASP, pulmonary artery systolic pressure; ECMO, extracorporeal membrane oxygenation; RF, renal failure.

unit and hospital stays were also similar in the two groups.

2) Overall survival

Among 77 survivors, late mortality (>30 days) occurred in 25 patients (32.5%). One-year and 5-year survival rates were 84.6% and 67.9% in group Y and 75.9% and 60.7% in group O, respectively. There was no difference in overall survival between the 2 groups (p=0.201) (Fig. 1). Multivariate analysis revealed that age ≥60 years was not a significant risk factor for overall survival; postoperative renal failure was the only significant risk factor for overall survival (p=0.011) (Table 4).

3) Event-free survival

Freedom from infection at 1 and 3 years was 72.5% and 67.8% in group Y and 63.6% and 63.6% in group O, respectively (p=0.586) (Fig. 2). Freedom from rejection (ISHLT grade ≥1B) at 1 year was 73.9% in group O and 45.9% in group Y, respectively (p=0.026) (Fig. 3).
The present study demonstrated two main findings. First, there were no significant differences in the early results and mid-term survival between the elderly patients (≥60 years) and young patients (<60 years) at the time of transplantation. Second, the elderly patients demonstrated a significantly higher freedom from rejection at 1 year.

Advanced age has traditionally been considered a relative contraindication for heart transplantation [5,6,11-13]. According to the 2011 report from the registry of the ISHLT, increasing recipient age remains an independent risk factor that adversely affects survival after heart transplantation [11]. Because of the critical shortage of donor organs, selection of candidates for transplantation is based on the potential for maximal benefit in terms of functional recovery and length of survival. In addition, advanced age is associated with shorter life expectancy and higher incidence of comorbidities such as hypertension and diabetes. Because of the rapid increase in the number of elderly patients, the number of candidates for transplantation older than 60 years has steadily increased [11,14]. However, the recipient age limit for heart transplantation is still a matter of debate [2,15]. Several studies have shown that heart transplantation in elderly patients could be performed successfully with acceptable morbidity and mortality and enhanced long-term survival, when compared with those of younger patients [2-4,16]. Recent advancements in postoperative care after heart transplantation, including the infection control protocols and immune suppression regimen, may have enabled that improvement [9]. In the present study, the early mortality rate was low and there were no differences in 1- or 5-year survival rates of groups Y and O.

Previous studies have demonstrated that the incidence of infection was higher in older patient groups [4,5,12,13]. In the present study, however, freedom from infection until postoperative 3 years was similar in the 2 groups. This seems to be due to improvements in the medications for infection control and immune suppression. Previous studies have also demonstrated that the incidence of acute cellular rejection was lower in older patients [3,5,16], and the present study also showed a similar result. Our immune suppression strategies have changed over time; however, the same strategies were used in the two groups. An age-related decrease in immune reactivity and T-cell function might be responsible for this effect [17]. In multivariable analysis, recipient age at the time of transplantation was not a risk factor for overall survival, but instead postoperative renal failure was the only significant risk factor.

There are limitations to the present study that must be recognized. First, this study was a nonrandomized, retrospective, observational study in a single institution. Second, the number of enrolled patients was relatively small for drawing definite conclusions. Third, the follow-up duration was different between the 2 groups because we began to perform heart transplantation in the elderly patients only recently.

The mortality and morbidity after heart transplantation did not increase significantly in the elderly patients (≥60 years), when compared with the younger patients (<60 years). Heart transplantation might also be considered to be a treatment option for elderly heart failure patients, although careful patient selection criteria should be applied considering donor shortage in the current era.

No potential conflict of interest relevant to this article was reported.

1. Goldstein DJ, Smego D, Michler RE. Surgical aspects of congestive heart failure. Heart Fail Rev 2006;11:171-92.
2. Blanche C, Blanche DA, Kearney B, et al. Heart transplantation in patients seventy years of age and older: a comparative analysis of outcome. J Thorac Cardiovasc Surg 2001;121:532-41.
3. Demers P, Moffatt S, Oyer PE, Hunt SA, Reitz BA, Robbins RC. Long-term results of heart transplantation in patients older than 60 years. J Thorac Cardiovasc Surg 2003;126:224-31.
4. Morgan JA, John R, Weinberg AD, et al. Long-term results of cardiac transplantation in patients 65 years of age and older: a comparative analysis. Ann Thorac Surg 2003;76:
11. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: twenty-eighth adult heart transplant report 2011. J Heart Lung Transplant 2011;30:1078-94.

12. Robin J, Ninet J, Tronc F, et al. Long-term results of heart transplantation deteriorate more rapidly in patients over 60 years of age. Eur J Cardiothorac Surg 1996;10:259-63.

13. Borkon AM, Muehlebach GF, Jones PG, et al. An analysis of the effect of age on survival after heart transplant. J Heart Lung Transplant 1999;18:668-74.

14. Fonarow GC. How old is too old for heart transplantation? Curr Opin Cardiol 2000;15:97-103.

15. Robbins RC. Ethical implications of heart transplantation in elderly patients. J Thorac Cardiovasc Surg 2001;121:434-5.

16. Baron O, Trochu JN, Treilhaud M, et al. Cardiac transplantation in patients over 60 years of age. Transplant Proc 1999;31:75-8.

17. Renlund DG, Gilbert EM, O'Connell JB, et al. Age-associated decline in cardiac allograft rejection. Am J Med 1987;83:391-8.